−4.15USD
−307.00 MUSD
117.00 MUSD
47.33 M
About Arcus Biosciences, Inc.
Sector
Industry
CEO
Terry J. Rosen
Website
Headquarters
Hayward
Employees (FY)
577
Founded
2015
ISIN
US03969F1093
FIGI
BBG00DQD26W3
Arcus Biosciences, Inc. engages in the development and commercialization of immunotherapies. It competes in the segments of the pharmaceutical, biotechnology and other related markets that develop immunotherapies for the treatment of cancer. The company was founded by Terry J. Rosen and Juan Carlos Jaen in 2015 and is headquartered in Hayward, CA.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of RCUS is 16.29 USD — it has decreased by 1.75% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NYSE exchange Arcus Biosciences, Inc. stocks are traded under the ticker RCUS.
Arcus Biosciences, Inc. is going to release the next earnings report on May 7, 2024. Keep track of upcoming events with our Earnings Calendar.
One year price forecast for Arcus Biosciences, Inc. has a max estimate of 70.00 USD and a min estimate of 24.00 USD.
RCUS earnings for the last quarter are −0.94 USD whereas the estimation was −1.13 USD which accounts for 16.77% surprise. Estimated earnings for the next quarter are −1.02 USD. See more details about Arcus Biosciences, Inc. earnings.
Arcus Biosciences, Inc. revenue for the last quarter amounts to 32.00 M USD despite the estimated figure of 27.28 M USD. In the next quarter revenue is expected to reach 28.30 M USD.
Yes, you can track Arcus Biosciences, Inc. financials in yearly and quarterly reports right on TradingView.
Like other stocks, RCUS shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Arcus Biosciences, Inc. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 16, 2024, the company has 577.00 employees. See our rating of the largest employees — is Arcus Biosciences, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Arcus Biosciences, Inc. EBITDA is −324.00 M USD, and current EBITDA margin is −276.92%. See more stats in Arcus Biosciences, Inc. financial statements.